Covington & Burling advised Bristol Myers Squibb on the deal, and Goodwin Procter advised 2seventy bio. Bristol Myers Squibb (NYSE: BMY) (“BMS”) announced its merger agreement...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised York Capital Management in its strategic growth investment in Comprehensive Rehab Consultants. William Blair acted as the sell-side investment banking advisor to CRC....
You must be a Standard 1 Year member to access this content.
Goodwin Procter is serving as legal counsel to SunMed, and Alston & Bird is serving as legal counsel to Avanos. SunMed announced it has entered into...
You must be a Standard 1 Year member to access this content.
Arnold & Porter advised Coherus Biosciences Inc. on the deal, and Goodwin advised Surface Oncology. Coherus Biosciences Inc. (Coherus) announced its acquisition of Surface Oncology Inc. (Surface),...
You must be a Standard 1 Year member to access this content.
Goodwin advised Haystack Oncology on the deal. Haystack Oncology announced its definitive agreement to be acquired by Quest Diagnostics (NYSE: DGX). Under the terms of the agreement,...
You must be a Standard 1 Year member to access this content.
Goodwin advised Aldrich Capital Partners on the deal. Aldrich Capital Partners announced its acquisition of Compliancy Group, LLC. Aldrich is a growth equity firm supporting disruptive innovation...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Aldrich Capital Partners on the deal. Aldrich Capital Partners announced its acquisition of PRIA Healthcare Management. Aldrich is a growth equity firm supporting disruptive...
You must be a Standard 1 Year member to access this content.
